drugset
drugset / Trial / NCT05004571

Safety, Tolerability, and Pharmacokinetics of EQU-001 in Healthy Volunteers

NCT05004571 ↗

Phase 1 Completed 81 enrolled Equilibre Biopharmaceuticals B.V.
RandomizedSequentialQuadruple-blindTreatment

Summary

This is a randomized, placebo-controlled, double-blinded single and multiple ascending dose (SAD and MAD) study of the safety, tolerability, and pharmacokinetics of EQU-001 in healthy volunteers.

Timeline

Start
2021-07-06
Primary completion
2021-09-04
Completion
2021-09-04

Drugs

EvaluationDrugModalityDoseRoute
Subject EQU-001 Unknown 10 mg Oral
Subject EQU-001 Unknown 20 mg Oral
Subject EQU-001 Unknown 40 mg Oral
Subject EQU-001 Unknown 80 mg Oral
Subject EQU-001 Unknown 120 mg Oral

Indications

No indication recorded.